Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.
The efficiency of Proproten-100 containing antibodies to S100 protein in ultralow doses and used to relieve somatovegetative and psychoneurological manifestations of the alcohol withdrawal syndrome was studied in a double-blind, placebo-controlled clinical trial. The preparation possessed anxiolytic, sedative, hypnagogic, and vegetostabilizing properties. Proproten-100 more rapidly relieved the alcohol withdrawal syndrome than standard drugs (by 2 times). Proproten-100 may used in combination with detoxicating and symptomatic drugs to treat patients with severe disorders. The preparation did not cause side effects. Our observations indicate that Proproten-100 may be used alone (monotherapy) or in combination with standard pharmaceutics for treatment of patients with the alcohol withdrawal syndrome.
Gofman
A G
AG
Moscow Institute of Psychiatry, Russian Ministry of Health.
Pyatnitskaya
I N
IN
Valentik
Yu V
YV
Krylov
E N
EN
Epstein
O I
OI
D000328:Adult; D000437:Alcoholism / Q000188:drug therapy*; D000906:Antibodies / Q000276:immunology* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009418:S100 Proteins / Q000276:immunology*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
D000906:Antibodies; D009418:S100 Proteins